2. Signaling Pathways
  3. Immunology/Inflammation
  4. Interleukin Related

Interleukin Related

IL

Interleukin Related

Related Products

PDF 1.53 MB

Interleukins are a group of cytokines (secreted proteins and signaling molecules) that were first seen to be expressed by white blood cells (leukocytes). The function of the immune system depends in a large part on interleukins, and rare deficiencies of a number of them have been described, all featuring autoimmune diseases or immune deficiency. The majority of interleukins are synthesized by helper CD4 T lymphocytes, as well as through monocytes, macrophages, and endothelial cells. They promote the development and differentiation of T and B lymphocytes, and hematopoietic cells. Interleukin receptors on astrocytes in the hippocampus are also known to be involved in the development of spatial memories in mice.

Interleukin Related Isoform Specific Products:

Interleukin Related Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-183367
    Anti-inflammatory agent 115
    		Inhibitor
    Anti-inflammatory agent 115 is a potent anti-inflammatory agent. Anti-inflammatory agent 115 reduces secretion of myeloperoxidase (MPO), TNF-α, IL-1β, and IL-6. Anti-inflammatory agent 115 decreases ear tissue thickness and neutrophil infiltration in 12-O-tetradecanoylphorbol-13-acetate (TPA) (HY-18739)-induced topical edema in mice. Anti-inflammatory agent 115 can be used for the research of inflammatory diseases.
    Anti-inflammatory agent 115
  • HY-182945
    IKZF2-degrader 5
    		Modulator
    IKZF2-degrader 5 is a highly efficient, highly selective, rapidly acting, and orally active IKZF2 molecular glue degrader. IKZF2-degrader 5 induces IKZF2 degradation via the Cullin-CRBN-dependent pathway. IKZF2-degrader 5 promotes the production of pro-inflammatory IL-2. IKZF2-degrader 5 attenuates the immunosuppressive function of regulatory T cells (Tregs). IKZF2-degrader 5 triggers rapid, significant, and sustained IKZF2 degradation in the spleen and thymus of mice. IKZF2-degrader 5 inhibits tumor growth. IKZF2-degrader 5 can be used for the research of B16F melanoma.
    IKZF2-degrader 5
  • HY-167153
    PNA5
    		Modulator
    PNA5 is a novel, blood-brain barrier permeable glycosylated angiotensin-(1-7) peptide and MasR agonist. PNA5 inhibits IL-7, increases IL-10. PNA5 inhibits ROS generation, decreases Iba-1 expression. PNA5 exhibits sustained cognitive protective effects. PNA5 rescues blunted cerebral functional hyperemia. PNA5 can be used in the research of inflammation-related brain diseases.
    PNA5
  • HY-P11220
    Hs02
    		Inhibitor
    Hs02 is a cationic amphiphilic antibacterial peptide derived from human proteins, and it is the membrane-active module of the core chimeric peptide Chim2. Hs02 exhibits broad-spectrum and potent antibacterial activity against various human pathogenic bacteria with the MIC for Staphylococcus aureus and Escherichia coli of as low as 2 μM, and the MBC is 2-4 μM. Hs02 primarily kills bacteria by disrupting the integrity of the bacterial cell membrane, and it has a relatively low selectivity for eukaryotic cell membranes. Hs02 induces the release of IL-12 but does not induce the release of IL-6, indicating its potential for pro-inflammatory or immune activation. Hs02 can be used in antibacterial and immunomodulatory research.
    Hs02
  • HY-P991285
    MEDI-9314
    		Inhibitor
    MEDI-9314 is a humanized monoclonal anti-CD124/IL4R/IL-4Rα antibody. MEDI-9314 can be used in research related to skin allergy.
    MEDI-9314
  • HY-W709413
    Panaxytriol
    		Inhibitor
    Panaxytriol is an active component of ginseng. Panaxytriol inhibits the nuclear translocation of NF-κB, thereby reducing the production of pro-inflammatory factors (such as TNF-α, IL-1β, IL-6) and nitric oxide (NO) induced by LPS (HY-D1056). Panaxytriol upregulates CYP3A4 by activating the nuclear receptor PXR/CAR. Panaxytriol improves motor dysfunction in a mouse model of brain inflammation. Panaxytriol can be used in the research of neurodegenerative diseases (such as Alzheimer's disease).
    Panaxytriol
  • HY-113468AS1
    3-O-Methyldopa-d3 hydrate
    		Inhibitor
    3-O-Methyldopa-d3 (hydrate) is the deuterium labeled 3-O-Methyldopa. 3-O-Methyldopa (3-Methoxy-L-tyrosine) hydrate is a metabolite of L-DOPA (HY-N0304) that can cross the blood-brain barrier (BBB). 3-O-Methyldopa hydrate inhibits the astrocyte-mediated protective effect of L-DOPA (HY-N0304) on dopaminergic neurons. In addition, 3-O-Methyldopa hydrate has certain antidepressant and neuroprotective activities. 3-O-Methyldopa hydrate can be used in the research of nervous system diseases such as depression and Parkinson's disease.
    3-O-Methyldopa-d<sub>3</sub> hydrate
  • HY-178471
    FABP4/5-IN-6
    		Inhibitor
    FABP4/5-IN-6 is an orally active, potent FABP4/5 inhibitor (Ki = 0.41/2.53 μM), showing low selectivity over FABP3 (Ki = 59.72 μM). FABP4/5-IN-6 inhibits the secretion of MCP-1 and IL-6 in Lipopolysaccharides (HY-D1056) (LPS)-induced THP-1 macrophage. FABP4/5-IN-6 exhibits significant anti-inflammatory effects and attenuates LPS-induced liver injury. FABP4/5-IN-6 has low hERG inhibition (LD50 > 2000 mg/kg). FABP4/5-IN-6 can be used for the study of Inflammation-related diseases.
    FABP4/5-IN-6
  • HY-P990602
    IMA-026
    		Inhibitor
    IMA-026 is a humanized antibody expressed in CHO cells that targets IL-13. IMA-026 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.88 kDa. The isotype control for IMA-026 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    IMA-026
  • HY-P991259
    MEDI-7836
    		Inhibitor
    MEDI-7836 is a humanized monoclonal antibody inhibitor that targets the interleukin-13 receptor. MEDI-7836 is promising for research of inflammation-related diseases.
    MEDI-7836
  • HY-162405
    STAT6-IN-12
    		Inhibitor
    STAT6-IN-12 is a potent STAT6 inhibitor with an IC50 of 50 nM. STAT6-IN-12 also inhibits Smad2/3 with an IC50 of 68 nM. STAT6-IN-12 inhibits TGFβ-dependent Smad2/3 signaling pathway, IL-4-dependent STAT6 signaling pathway, and cellular inflammatory responses. STAT6-IN-12 can be used for the research of inflammation.
    STAT6-IN-12
  • HY-P992370
    HPN601
    		Inhibitor
    HPN601 is a protease-activated EpCAM-targeting T-cell engager that binds EpCAM competitively and induces T-cell mediated tumor cell killing. HPN601 binds to EpCAM, CD3e and albumin; albumin binding extends its half-life, while masking groups keep the molecule inert outside the tumor microenvironment. HPN601 significantly reduces the release levels of IFN-γ, IL-2, IL-6 and IL-10. HPN601 can be used in research related to cancers such as breast cancer and gastric cancer.
    HPN601
  • HY-175277
    PIM1-IN-8
    		Inhibitor
    PIM1-IN-8 is a PIM1/p65 pathway inhibitor. PIM1-IN-8 suppresses the expression of α-SMA and collagen I in activated fibroblasts and blocks TGF-β induced migration. PIM1-IN-8 alleviates pulmonary fibrosis in a Bleomycin (BLM) (HY-17565A)-induced pulmonary fibrosis mice model. PIM1-IN-8 can be used for the study of idiopathic pulmonary fibrosis (IPF).
    PIM1-IN-8
  • HY-141535
    IL-17 modulator 1
    		Modulator
    IL-17 modulator 1 is an orally active, highly efficacious small molecule IL-17 modulators extracted from patent WO 2020127685. IL-17 modulator 1 can be used for the research of preventing, researching or ameliorating a variety of diseases including psoriasis, ankylosing spondylitis and psoriatic arthritis.
    IL-17 modulator 1
  • HY-N0604R
    Ginsenoside Rh1 (Standard)
    		Inhibitor
    Ginsenoside Rh1 (Standard) is the analytical standard of Ginsenoside Rh1. This product is intended for research and analytical applications. Ginsenoside Rh1 (Prosapogenin A2) inhibits the expression of PPAR-γ, TNF-α, IL-6, and IL-1β.
    Ginsenoside Rh1 (Standard)
  • HY-183339
    IL-6/RIPK3-IN-1
    		Inhibitor
    IL-6/RIPK3-IN-1 is an inhibitor of IL-6, RIPK3 and BRD4, with IC50 values of 0.22, 1.32 and 5.91 μM, respectively. IL-6/RIPK3-IN-1 can be used in studies related to inflammation and tissue damage.
    IL-6/RIPK3-IN-1
  • HY-148258A
    GDC-2394 sodium
    		Inhibitor
    GDC-2394 (Compound 20) sodium is an orally active and selective NLRP3 inhibitor, and also inhibits IL-1β with IC50s of 0.4 μM (human IL-1β) and 0.1 μM (mouse IL-1β). GDC-2394 sodium inhibits NLRP3-induced caspase-1 activity without inhibiting NLRC4-dependent inflammasome activation. GDC-2394 sodium could be used to study gouty arthritis.
    GDC-2394 sodium
  • HY-113494R
    Sitostanol (Standard)
    		Activator
    Stigmastanol (Standard) is the analytical standard of Stigmastanol. This product is intended for research and analytical applications. Stigmastanol is a 6-amino derivative. Stigmastanol can be isolated from Hypericum riparium. Stigmastanol increases the secretion of IL-2 and IL-10. Stigmastanol reduces the maximum mitochondrial respiration of cells. Stigmastanol has beneficial effects on the weakened immune function of asthma.
    Sitostanol (Standard)
  • HY-P3736
    Myelopeptide-2
    		Inducer
    Myelopeptide-2 is a peptide originally isolated from the supernatant of porcine bone marrow cell cultures, can restore mitogenic reactivity of human T lymphocytes inhibited by HL-60 leukemia cells or measles virus conditions. Myelopeptide-2 also recover depressed interleukin-2 (IL-2) synthesis and interleukin-2 receptor (IL-2R) expression. Myelopeptide-2 involves in immunity homeostasis, is perspective to be applied in antitumor and antivirus research.
    Myelopeptide-2
  • HY-145675A
    (R)-TCB2
    (R)-TCB2 is the R-enantiomer of TCB2. TCB2 is a potent anti-human interleukin-2 antibody, facilitates heterodimeric IL-2 receptor signaling and improves anti-tumor immunity.
    (R)-TCB2
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
Interleukin Related Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.